Zusammenfassung
Den Begriff funktionelle Durchblutungsstörungen verwendet man für Krankheitsbilder, bei denen es zu einer Engstellung oder Erweiterung der Gefäße kommt, ohne dass organische Gefäßveränderungen vorhanden sind.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Allen EV, Brown GE (1932) Raynaud’s disease: a critical review of minimal requisites for diagnosis. Am J Med Sci 183(2):187–200
Baldwin ZK, Ceraldi CC (2003) Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg 37(3):676–678
Belch JJ, Newman P, Drury JK, McKenzie F, Capell H, Leiberman P, Forbes CD, Prentice CR (1983) Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud’s syndrome: a double-blind controlled trial. Lancet 1:313–315
Bettoni L, Geri A, Airo P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R (2002) Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21(3):244–250
Bollinger A, Schlumpf M (1976) Finger blood flow in healthy subjects of different age and sex and in patients with primary Raynaud’s disease. Acta Chir Scand Suppl 465:42–47
Bollinger A, Mahler F, Meier B (1977) Velocity patterns in nailfold capillaries of normal subjects and patients with Raynaud’s disease and acrocyanosis. Bibl Anat 16:142–145
Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, Erdmann E, Rosenkranz S (2006) Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud’s disease. Arch Intern Med 166(2):231–233
Coffman JD, Cohen RA (1988) Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur J Clin Invest 18(3):309–313
Dowd PM, Martin MF, Cooke ED, Bowcock SA, Jones R, Dieppe PA, Kirby JD (1982) Treatment of Raynaud’s phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol 106(1):81–89
Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42(12):2646–2655
Eadie MJ (2001) Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs 15(2):105–118
El Menyar AA (2006) Drug-induced myocardial infarction secondary to coronary artery spasm in teenagers and young adults. J Postgrad Med 52(1):51–56
Friedman EA, Harris PA, Wood AJ, Stein CM, Kurnik D (2007) The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud’s phenomenon. Clin Pharmacol Ther 81(4):503–509
Fries R, Shariat K, von Wilmowsky H, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985
Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, Cugno M, Bottasso B, Stabilini R (2001) Treatment of Raynaud’s phenomenon with intravenous prostaglandin E1 alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol 28(4):786–794
Herskowitz MM, Gillego V, Ward M, Wright G (2002) Cocaine-induced mesenteric ischemia: treatment with intra-arterial papaverine. Emerg Radiol 9(3):172–174
Hirschl M, Katzenschlager R, Francesconi C, Kundi M (2004) Low level laser therapy in primary Raynaud’s phenomenon – results of a placebo controlled, double blind intervention study. J Rheumatol 31(12):2408–2412
Husmann MJ, Barton M, Jacomella V, Silvestro V, Amann-Vesti B (2006) Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis. J Vasc Surg 44(5):993–997
Jamieson GG, Ludbrook J, Wilson A (1971) Cold hypersensitivity in Raynaud’s phenomenon. Circulation 44:254–264
Kuhnert SM, Phillips WJ, Davis MD (1999) Lidocaine and mexiletine therapy for erythromelalgia. Arch Dermatol 135(12):1447–1449
Kyle MV, Belcher G, Hazleman BL (1992) Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud’s phenomenon. J Rheumatol 19(9):1403–1406
LeRoy EC, Medsger TA (1992) Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 10(5):485–488
Levien TL (2006) Phosphodiesterase inhibitors in Raynaud’s phenomenon. Ann Pharmacother 40(7–8):1388–1393
Maga P, Kuzdzal J, Nizankowski R, Szczeklik A, Sladek K (2007) Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease. J Thorac Cardiovasc Surg 133(6):1428–1433
Mahler F, Meier B, Frey R, Bollinger A, Anliker M (1977) Reaction of red blood cell velocity in nailfold capillaries to local cold in patients with vasospastic disease. Bibl Anat 16:155–158
Mahler F, Saner H, Boss CH, Annaheim M (1987) Local cold exposure for capillaroscopic examination of patients with Raynaud’s syndrome. Microvasc Res 33:422–427
Maricq HR, Spencer-Green G, LeRoy EC (1975) Abnormal capillary patterns and systemic disease in scleroderma (progressive systemic sclerosis). Bibl Anat 13:248–249
Maricq HR, LeRoy EC, D'Angelo WA, Medsger TA, Rodnan GP, Sharp GC, Wolfe JF (1980) Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23(2):183–189
Meli M, Gitzelmann G, Koppensteiner R, Amann-Vesti BR (2006) Predictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol 25(2):153–158
Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, Kirby JD (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double blind randomized study. BMJ 298:561–564
Riccardi MT, Chialà A, Lannone F, Grattagliano V, Covelli M, Lapadula G (2007) Treatment of digital ulcers in systemic sclerosis with endothelin-1 receptor antagonist (bosentan). Reumatismo 59(2):135–139
Rusch NJ, Shepherd JT, Vanhoutte PM (1981) The effect of profound cooling on adrenergic neurotransmission in canine cutaneous veins. J Physiol 311:57–65
Rustin MH, Almond NE, Beacham JA, Brooks RJ, Jones DP, Cooke ED, Dowd PM (1987) The effect of captopril on cutaneous blood flow in patients with primary Raynaud’s phenomenon. Br J Dermatol 117(6):751–758
Smith CD, McKendry RVR (1982) Controlled trial of nifedipine in the treatment of Raynaud’s phenomon. Lancet 2:1299–1301
Tosi S, Marchesoni A, Messina K, Bellintani C, Sironi G, Faravelli C (1987) Treatment of Raynaud’s phenomenon with captopril. Drugs Exp Clin Res 13(1):37–42
Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenez S, Mayes M, Clements PJ, Weiner SR, Porter J, Ellman M, Wise C, Kaufman LD, Williams J, Dole W (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120(3):199–206
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Amann-Vesti, B. (2020). Funktionelle Durchblutungsstörungen. In: Debus, E., Gross-Fengels, W. (eds) Operative und interventionelle Gefäßmedizin. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-53380-2_16
Download citation
DOI: https://doi.org/10.1007/978-3-662-53380-2_16
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-53378-9
Online ISBN: 978-3-662-53380-2
eBook Packages: Medicine (German Language)